Zhangzhou Pientzehuang Pharmaceutical. stock
600436.SSSHHZhangzhou Pientzehuang Pharmaceutical., Ltd, HealthcareISIN CNE000001F21
58Score 58 out of 100, Neutral
Price and trend
61 / 100
Price history
−29% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 4.9% below it.
Since January 2025 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 61).
The price is 29% below its 52-week high. Largest decline in 20 years: 78% (July 2021 to June 2026).
Chart figures for advanced users
- SMA 50$18.55
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$20.48
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)61
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$16.20
- The lowest closing price of the last twelve months.
- Resistance$27.33
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Zhangzhou Pientzehuang Pharmaceutical., Ltd belongs to the Drug Manufacturers (General) industry (China) and, with a market value of $11.75B, is number 23 of 27 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.35B (down 16.6% year on year) and earnings of $323.72M (down 27.5%).
- For fiscal 2026, analysts expect on average revenue of $1.26B (down 7%) and adjusted earnings per share of $0.48.
Show more
- MEQIRI Score 58 out of 100 (Neutral): rank 290 of 702 in Healthcare, median 53.
- Our model puts fair value at $14.82, with the price 31% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $333.78M, financial debt $162.28M.Stability 94
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 78
- High return on capitalReturn on invested capital 16.7% in fiscal 2025, Healthcare sector median 9.2%.Profitability 61
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are stability and fundamentals, while growth and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $11.40 and expensive above $21.17 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 7.3%. At 8.3% the fair value would be $11.98, at 6.3% it would be $19.10.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 19.1% on the twelve months before. Revenue has grown strongly since 2006, at around 16% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 36%, operating 28%, net 24%. Last 12 months: net 17%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 12 Apr 2027in 150 days
- Last reported
- 30 Oct 2026EPS reported $0.05 (expected $0.18)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 5.7% since 24 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $0.48−5.6%
- Revenue
- $1.26B−1.8%
- Earnings per share
- $0.53−5.7%
- Revenue
- $1.3B−2.4%
MEQIRI has stored the estimates since 24 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Zhangzhou Pientzehuang Pharmaceutical.
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 58
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (General)
The next larger and next smaller companies by market value
- Daiichi Sankyo4568.T $32.6B73
- Astellas Pharma4503.T $30.07B87
- OrionORNBV.HE $15.97B86
- CSPC Pharmaceutical Group1093.HK $12.16B79
- GrifolsGRF.MC $8.79B66
- Ono Pharmaceutical4528.T $7.32B74
- OrganonOGN $3.65B59
- VirbacVIRP.PA $3.32B67
ETFs that hold Zhangzhou Pientzehuang Pharmaceutical.
Held by 42 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| HSBC MSCI China A UCITS ETF USDH41K | 0.32% | 0.30% | €68.31M |
| Xtrackers Harvest CSI300 UCITS ETF 1DRQFI | 0.20% | 0.65% | €251.68M |
| Xtrackers Harvest CSI A500 UCITS ETF 1DAH50 | 0.17% | 0.65% | €10.81M |
Show 5 more
| UBS MSCI China Universal UCITS ETF USD disUETC | 0.06% | 0.30% | €132.6M |
| Amundi MSCI China ESG Selection Extra UCITS ETF AccLCHI | 0.05% | 0.65% | €564.13M |
| iShares MSCI EM Consumer Growth UCITS ETFCEMG | 0.04% | 0.60% | €31.52M |
| HSBC MSCI China UCITS ETFH4ZP | 0.03% | 0.28% | €865.89M |
| Franklin FTSE China UCITS ETFFLXC | 0.03% | 0.19% | €1.43B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Oct 2025)
- Valuation signal Fairly valued since 7 Nov 2026, previously Overvalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.